Literature DB >> 17363525

Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.

Morgan Rouprêt1, Vincent Hupertan, David R Yates, James W F Catto, Ishtiaq Rehman, Mark Meuth, Sylvie Ricci, Roger Lacave, Géraldine Cancel-Tassin, Alexandre de la Taille, François Rozet, Xavier Cathelineau, Guy Vallancien, Freddie C Hamdy, Olivier Cussenot.   

Abstract

PURPOSE: The diagnosis of localized prostate cancer is difficult due to a lack of cancer-specific biomarkers. Many patients require repeat prostate biopsies to diagnose the disease. We investigated whether aberrant promoter hypermethylation in prostatic fluid could reliably detect prostate cancer. EXPERIMENTAL
DESIGN: Urine samples were collected after prostate massage from 95 patients with localized prostate cancer undergoing radical prostatectomy (63 pT(1), 31 pT(2), and 1 pT(3)) and from 38 control patients. Ten genes (GSTP1, RASSF1a, ECDH1, APC, DAPK, MGMT, p14, p16, RARbeta2, and TIMP3) were investigated using quantitative real-time methylation-specific PCR. Receiver operator curves were generated.
RESULTS: The frequency of gene methylation ranged from 6.3% (p14) to 83.2% (GSTP1) in prostate cancer patients. At least one gene was hypermethylated in 93% of cancer patients. The specificity of methylation was 0.74. Methylation was significantly more frequent (P < 0.05) in cancer than control patients for all genes except p14 and p16. According to receiver operator curve analysis, the four-gene combination of GSTP1 (0.86), RASSF1a (0.85), RARbeta2 (0.80), and APC (0.74) best discriminated malignant from nonmalignant cases. The sensitivity and accuracy of this four-gene set were 86% and 89%, respectively.
CONCLUSIONS: The presence of aberrant methylation in urinary cells obtained after prostate massage is significantly associated with prostate cancer. A panel of four genes could stratify patients into low and high risk of having prostate cancer and optimize the need for repeat prostatic biopsies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363525     DOI: 10.1158/1078-0432.CCR-06-2467

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Quantitative ratiometric discrimination between noncancerous and cancerous prostate cells based on neuropilin-1 overexpression.

Authors:  Alessia Pallaoro; Gary B Braun; Martin Moskovits
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

Review 3.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

4.  The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.

Authors:  Yu-Zheng Ge; Lu-Wei Xu; Rui-Peng Jia; Zheng Xu; Yu-Ming Feng; Ran Wu; Peng Yu; Yan Zhao; Zan-Long Gui; Si-Jia Tan; Qun Song
Journal:  Tumour Biol       Date:  2013-12-19

Review 5.  APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.

Authors:  Yang Chen; Jie Li; Xiaoxiang Yu; Shuai Li; Xuerong Zhang; Zengnan Mo; Yanling Hu
Journal:  Eur J Hum Genet       Date:  2013-01-09       Impact factor: 4.246

6.  Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.

Authors:  Masatsugu Hiraki; Yoshihiko Kitajima; Seiji Sato; Jun Nakamura; Kazuyoshi Hashiguchi; Hirokazu Noshiro; Kohji Miyazaki
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

Review 7.  Urinary biomarkers for prostate cancer: a review.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Asian J Androl       Date:  2013-03-25       Impact factor: 3.285

8.  CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.

Authors:  Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Craig G Rogers; Xiaohui Lin; Leslie A Mangold; Bruce Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

Review 9.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

10.  Newer potential biomarkers in prostate cancer.

Authors:  Jonathan L Wright; Paul H Lange
Journal:  Rev Urol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.